never too late to quit

PharmacoEconomics & Outcomes News 589 - 17 Oct 2009 Never too late to quit. . . Smoking cessation in patients with a smoking-related disease appears at least as cost effective as active disease treatment, according to research presented at the 19th Annual Congress of the European Respiratory Society. To compare these two approaches, researchers reviewed literature within the Cost-Effectiveness Analysis Registry and Medline for cost utility studies in patients with chronic obstructive pulmonary disease (COPD), cardiovascular disorders and lung cancer. Fifteen studies on smoking cessation were identified and reviewed. Within these studies, incremental cost- effectiveness ratios for smoking cessation ranged from $34 000 per QALY gained, to cost saving/dominant in the best case (median $1117/QALY gained). By contrast, the median costs for the treatment of COPD, cardiovascular disease and lung cancer ranged between $22 000-$44 000 per QALY gained. It was concluded that, in patients with smoking related diseases, smoking cessation is at least as cost effective as treatment of the disease itself. Dollerup J, et al. Smoking cessation compared to treatment of COPD and other smoking-related diseases using cost-effectiveness evidence. 19th Annual Congress of the European Respiratory Society : abstr. 4647, 12 Sep 2009. 803000873 1 PharmacoEconomics & Outcomes News 17 Oct 2009 No. 589 1173-5503/10/0589-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved

Post on 23-Dec-2016

217 views

Category:

Documents

0 download

Report

Download

Embed Size (px):

TRANSCRIPT

PharmacoEconomics & Outcomes News 589 - 17 Oct 2009

Never too late to quit. . .Smoking cessation in patients with a smoking-related

disease appears at least as cost effective as activedisease treatment, according to research presented atthe 19th Annual Congress of the European RespiratorySociety.

To compare these two approaches, researchersreviewed literature within the Cost-EffectivenessAnalysis Registry and Medline for cost utility studies inpatients with chronic obstructive pulmonary disease(COPD), cardiovascular disorders and lung cancer.Fifteen studies on smoking cessation were identified andreviewed. Within these studies, incremental cost-effectiveness ratios for smoking cessation ranged from$34 000 per QALY gained, to cost saving/dominant inthe best case (median $1117/QALY gained). By contrast,the median costs for the treatment of COPD,cardiovascular disease and lung cancer ranged between$22 000-$44 000 per QALY gained. It was concludedthat, in patients with smoking related diseases, smokingcessation is at least as cost effective as treatment of thedisease itself.Dollerup J, et al. Smoking cessation compared to treatment of COPD and othersmoking-related diseases using cost-effectiveness evidence. 19th Annual Congressof the European Respiratory Society : abstr. 4647, 12 Sep 2009. 803000873

NEVER TOO YOUNG TO LEAD, NEVER TOO OLD TO LEARN€¦ · NEVER TOO YOUNG TO LEAD, NEVER TOO OLD TO LEARN Continuing Kofi Annan’s legacy ANNUAL REVIEW 2018. THE ELDERS Mary Robinson,

Never Quit Challenge, Jet ski Adventure

Never Too _____

guide to quit smoking-english-website friendly · smoking for a long time, but it is never too late to quit. Quitting smoking at any age has major beneﬁts to your body. Even if

Yanni - Never Too Late

Excellent never quit

Never Too Early, Never Too Late · Never Too Early, Never Too Late: Social and Biological Influences on Health and Disease Over the Lifecourse Edited by Amanda Sacker and Mel Bartley

Never Quit Challenge Awards & Fundraiser at the Stone Bistro

Itâ€™s Never Too Late, or Too Early

never too late - MinnesotaIT’S NEVER TOO EARLY IT’S NEVER TOO LATE A BOOKLET ABOUT PERSONAL FUTURES PLANNING For Persons With Developmental Disabilities, Their Families and Friends,

Phoenix Patriot Foundation - 2014 Never Quit Challenge

Never Never Quit